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Abstract
Background: Aspergillus fumigatus, a widely distributed fungus, has been implicated in causing life
threatening infections as well as severe asthma and allergic diseases in man. Allergic affliction like
allergic bronchopulmonary aspergillosis (ABPA) is a disabling lung disease frequently seen in
patients with asthma and cystic fibrosis. Immunodiagnosis of the former is comparatively easier due
to the availability of purified antigens and sensitive methods. However, this is not true with cystic
fibrosis patients where the prevalence of ABPA is fairly high and the morbidity and mortality are
significant.
Methods: In the present study, we have evaluated purified recombinant allergens from A.
fumigatus, namely Asp f 1, f 2, f 3, f 4, and f 6 using ELISA and a semi-automated method
(ImmunoCAP). We studied 17 patients each from cystic fibrosis with ABPA, and cystic fibrosis with
asthma, 22 cystic fibrosis with no ABPA or asthma, and 11 age matched controls.
Results: The results indicate that no antigen, antibody or method is capable of differentiating cystic
fibrosis (CF) with ABPA from other CF patients, although some allergens showed strong reaction
or showed more prevalence among the patients studied.
Conclusion: When results of several allergens such as Asp f 1, f 2, f 3, f 4, and f 6 in their binding
to IgA, IgG, and IgE antibodies were analyzed, a more strong discrimination of CF patients with
ABPA was possible from the other groups studied.
Background
Allergic bronchopulmonary aspergillosis (ABPA) is a dis-
abling allergic disease frequently seen in patients with
asthma and cystic fibrosis [1,2]. The prevalence of ABPA
has been estimated to be around 1 to 2% in asthmatics
and up to 15% among patients with cystic fibrosis [3].
Over 60 percent of the patients with cystic fibrosis (CF)
had atopy and the prevalence of ABPA among those
patients have been reported to be over 20% compared to
2% in non-atopic CF patients. Immediate cutaneous reac-
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tivity to A. fumigatus (Af) antigen was detected in 59% of
patients, while enhanced IgG antibodies to Af was
detected in 51%, and precipitating antibodies in 42% of
ABPA-CF patients. Peripheral blood eosinophilia was evi-
dent only in one-third of the patients [4]. The available
information thus indicate that Aspergillus-specific IgE and
IgG are elevated in some patients, while in others no such
elevation has been detected, and the values are frequently
comparable to CF patients without ABPA. Similarly, total
serum IgE and skin tests with Af antigens, antigen-specific
histamine release, and pulmonary function tests all have
limitations in the diagnosis of ABPA with CF [3,5]. Thus,
it is evident that the diagnosis of ABPA-CF is extremely
difficult compared to ABPA without CF and the laboratory
results are frequently inconclusive. Although a number of
Af allergens have been cloned and expressed, most of
them have not been evaluated simultaneously for their
IgE binding and diagnostic significance. Most of the stud-
ies have been carried out using crude Af antigens or, less
frequently, with recombinant allergens by ELISA and radi-
oimmunoassays [6-9]. Recently, semi-automatic methods
have been introduced using recombinant allergens of
Aspergillus. In the present study, we employed both ELISA
and ImmunoCAP (UniCAP, Pharmacia) utilizing some of
the promising recombinant and crude extracts of Af to
investigate specific IgE and other antibody isotypes in the
sera of different groups of patients with CF and Af-
induced allergy and normal controls. The results indicate
that no single allergen specificity or antibody isotype spe-
cificity can reliably identify ABPA with CF, although
majority of such patients showed significantly increased
polyclonal response to multiple antigens.
Materials and methods
Human sera
Sera from four different groups of subjects were studied
for various antibodies to Aspergillus allergens. All the 17
ABPA patients were diagnosed according to the criteria
recommended by Stevens et al [3]. These include clinical
deterioration (cough, wheeze, exercise intolerance, exer-
cise induced asthma, decline of pulmonary function,
increased sputum) not attributed to another etiology,
total serum IgE over 1000 IU/ml (2400 ng/mL), immedi-
ate cutaneous reactivity to Aspergillus or in vitro presence of
serum IgE antibody to Af and either precipitins to Af anti-
gens or abnormal chest radiographs showing infiltrates or
mucus-plugging. Included in the study was a set of17 CF
patients with asthma and positive epicutaneous test
responses to Af antigen but no other criteria of ABPA
described above. In addition, 22 subjects with CF but no
atopy and 11 sera from apparently normal control sub-
jects were also studied. The institutional human study
committees of the respective institutions have approved
this research.
Aspergillus fumigatus antigens
Aspergillus fumigatus extract
The crude culture filtrate extract was made as described
before [6,10]. In brief; the fungus was grown in a defined
medium for up to 3 weeks in stationary cultures at room
temperature. The culture filtrates were separated from
mycelial mat and freeze dried after extensive dialysis. The
extracts were evaluated for their immunochemical charac-
teristics, and the results were evaluated in comparison
with in-house standards. Recombinant allergens Asp f 1,
Asp f 2, Asp f 3, Asp f 4, and Asp f 6 were obtained by
expressing the cloned genes as described before [6-8].
Expressed proteins were also characterized by immuno-
chemical methods as described before [10-12].
Enzyme linked immunosorbent assay (ELISA)
ELISA using Af extracts and recombinant proteins were
carried out as described before [6]. In brief, the method
used was as follows: The microtiter plates were coated
with 5 μg/ml of crude Af extract or the recombinant aller-
gens dissolved in phosphate buffered saline (PBS) pH 7.2
for 1 hour at room temperature. The plates were sealed
and kept at 4°C overnight and washed in PBS containing
0.05% Tween-20 (PBS-T). After washing the plate, the
wells were blocked with PBS-Tween-20 containing 0.5%
bovine serum albumin for 1 hour. This was followed by
washing the wells three times with PBS-T. Serum dilutions
were then added to each well and the plates incubated at
room temperature for 3 hours. The plates were washed as
before and mouse anti-human IgE (biotinylated) was
added and incubated for 1 hour. After washing, streptavi-
din peroxidase was added to the wells and the plates incu-
bated again for 1 hour. The enzyme reactivity was
developed by adding orthophenylene diamine in citrate
buffer. The color development was stopped using 2N
H2S04 and optical density (OD490) measured using an
ELISA reader. All the dilutions of sera and reagents and the
antigen concentrations used in the solid phase were deter-
mined after checkerboard titrations. We studied the spe-
cific antibodies belonging to the isotypes of IgE, IgG, IgG1,
G2, G3, G4, IgA, IgA1, and IgA2 against crude Af antigens
and recombinant Af allergens asp f 1, f 2, f 3, f 4, and f 6.
ImmunoCAP studies
All sera were also tested for Af specific antibodies using
UniCAP 100 assay (CAP; Pharmacia/Upjohn, Kalamazoo,
MI). A. fumigatus total extract and recombinant Af aller-
gens Asp f 1, f 2, f 3, f 4, and f 6 coupled ImmunoCAPs
were used to detect specific IgE in the sera. The procedure
followed was exactly according to the protocol recom-
mended by the manufacturer. An ImmunoCAP class of 1
or more (0.35 kUA/L) was considered to be positive. Same
lot of ImmunoCAPs and reagents were used for all the
study.
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Statistical analysis
The mean optical density (OD) values for all the different
allergens and antibody types and isotypes were calculated
and the results of ELISA and ImmunoCAPs analyzed by
multivariate analysis of variance (MANOVA). A 'p' value
of 0.05 was considered significant. Post hoc univariate
analysis of variance was performed to find significant
allergens and antibody isotypes and subtypes [13].
To study the effect of all allergens and antibody isotypes,
a discriminant analysis was performed combining all the
variables. The discriminant analysis creates a scale or
scales based on all the combined variables to allow the
maximum possible separation between the groups. This
scale(s) is called the discriminant function. The stepwise
procedure of the discriminant analysis eliminates the
insignificant variables. Deletion of these insignificant var-
iables is needed in order to minimize the estimation
errors of the discriminate function. It also provides varia-
bles that are not needed in order to achieve the maximum
possible separation between groups. Based on the discri-
minant scores, the various groups such as CF, normal, CF
with asthma and CF with ABPA were assessed. The per-
centage of correct classification was used to measure the
strength of the discriminant analysis.
Results
Specific IgE antibodies in the sera of subjects
IgE antibodies against various Aspergillus antigens
detected by ImmunoCAP and ELISA are shown in Figure
1. Normal subjects and CF patients with no asthma or
ABPA failed to demonstrate IgE to any of the recombinant
allergens studied. However, the Aspergillus extract used in
ImmunoCAP reacted with IgE from CF patients with and
without ABPA. All five recombinant allergens showed
strong reactivity with IgE from CF patients with asthma
and CF with ABPA making it difficult to differentiate the
different groups. Although, ELISA failed to detect specific
IgE in the sera of normal subjects, significant reactivity
was noted with CF asthma and CF-ABPA by all tested
allergens. Among the various antigens tested, Asp f 2, f 3,
f 4, and f 6 showed stronger reactivity with CF-ABPA com-
pared to other groups by both ELISA and ImmunoCap
assays. Asp f 6 showed strong reactivity with fewer
patients, who failed to show significant reactivity with
other antigens. Notably, the IgE antibody levels in the sera
of CF-ABPA against both recombinant Af allergens as well
as crude Af extract were higher than in CF with asthma,
but due to similar reactivity of some patients in both
groups, the usefulness of specific IgE for differential diag-
nosis is questionable as there were no significant differ-
ences in the response of specific IgE to Aspergillus
allergens. None of the normal controls showed any Af
specific IgE in their sera against the antigens tested, while
CF patients demonstrated only low levels of specific IgE.
ImmunoCAP of crude Af antigens showed specific IgE
antibody levels in all the tested patients from CF-ABPA
and CF asthma.
IgE antibodies against various recombinant allergens and crude Aspergillus extractFigure 1
IgE antibodies against various recombinant allergens and 
crude Aspergillus extract. A. IgE measured by ImmunoCAP. B. 
IgE measured by ELISA.
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Total serum IgE
Although most ABPA-CF patients showed elevated total
serum IgE, there was considerable overlap between CF-
ABPA and CF-asthma. Occasionally, CF patients also
showed elevated total IgE comparable to ABPA-CF.
Aspergillus specific IgG and IgA antibodies
The IgG isotypic responses to the antigens tested showed
considerable variation in all groups of patients studied
(Figure 2). Only an occasional normal control showed
antibody to these allergens when studied by ELISA. Of the
11 normal subjects studied, only one showed IgG isotype
response against all the different allergens studied. Two
additional normal subjects also showed reactivity to Asp f
4 by ELISA. No significant difference was detected in the
IgG1, IgG2, and IgG3 antibodies against the various aller-
gens studied. However, IgG4 was consistently elevated in
both ABPA CF and CF asthma patients while significant
increases were also detected in some patients with uncom-
plicated CF. Normal controls also showed a specific IgG1
responses to crude Aspergillus antigen. IgG4 antibody lev-
els showed considerable variation among the sera studied
from different groups of subjects. Among the IgG isotypes
studied, IgG1 and IgG4 showed higher binding with most
of the antigens studied.
IgA antibody responses against different allergens in vari-
ous groups showed no major differences (Figure 2). Crude
Aspergillus antigen gave consistently higher values when
studied for IgA and IgA subclasses. A number of normal
controls also showed strong reactivity with IgA2. Although
no significant antibody response against any of the differ-
ent antigens studied was discernible, a marked IgA1
response was detected in ABPA-CF patients against most
tested recombinant allergens.
Cannonical-discriminant analysis
The results from different assays were analyzed using dis-
criminant analysis. A preliminary screening of stepwise
procedure eliminated IgE and IgG3 binding of the serum
to Asp f 1, IgG1, IgG3, and IgG4 binding of the sera to Asp
f 2, IgG4 binding of the sera to Asp f 3, IgG2, IgG3, and IgG4
binding of the serum to Asp f 4 and IgA2, IgG2, IgG3, and
IgG4 binding of the sera to Asp f 6. IgE, IgA, IgA1, and IgG1
binding to Asp f 6 was found to be important because
eliminating these parameters resulted in significantly
large classification errors. The remaining variables when
used in the analysis demonstrated significant discrimina-
tion between CF asthma, CF-ABPA, CF, and normal
groups (Figure 3). The figure 3 displays the first two-dis-
criminant scores (a pair of linear functions of all the inclu-
sive variables) demonstrate significant discrimination
between CF asthma and CF-ABPA groups.
To ascertain the power of this analysis, a classification
analysis was performed in which patients were classified
to one of the four groups (CF asthma, CF-ABPA, CF, and
normal) based on the discriminant functions [13]. Over-
all 95% of the subjects belonging to the various groups
were correctly classified. All normal subjects and CF-ABPA
patients were correctly classified, while only one out of 22
uncomplicated CF patients, and one out of 17 CF patients
with asthma were incorrectly classified using the present
system (Table 1).
When crude antigen was used in ImmunoCAP or in
ELISA, considerable overlap was shown by different
groups of patients. However, ELISA identified over 85% of
ABPA-CF patients, while no differentiation was possible
with IgE ImmunoCAP between CF-ABPA and CF asthma
or CF patients.
Discussion
The diagnosis of CF-ABPA is a more difficult task than
diagnosing ABPA without cystic fibrosis [3]. The diagnos-
tic criteria developed to differentiate this disease is also
different from those followed in the diagnosis of non-CF-
ABPA. Elevated serum total IgE, a common feature consid-
ered significant in the diagnosis of ABPA without cystic
fibrosis is not as reliable in the differential diagnosis of
ABPA with cystic fibrosis [1,12]. Skin test reactivity and
the presence of specific IgG are also considered important
in the diagnosis of ABPA with and without CF. The multi-
functional discriminant analysis using IgE, IgG, IgA and
the different recombinant allergens yielded significant
results in the differentiation of different patient groups.
It has been shown that crude extract from A. fumigatus is a
useful reagent for demonstrating specific IgG and IgE
from most ABPA patients [14-17]. However, a number of
CF patients with and without asthma also demonstrated
high levels of both antibodies. Purified recombinant aller-
gens have shown more specificity compared to other aller-
gen preparations when ABPA patients without CF were
studied [6,18]. Asp f 1 showed non-specific reactivity with
normal controls and CF patients with and without ABPA.
However, ABPA patients without cystic fibrosis consist-
ently demonstrate specific antibodies to Asp f 2 compared
to other purified recombinant Af allergens [6,9]. In com-
bination with Asp f 3, f 4, and f 6 a number of patients
with ABPA demonstrated specific IgE in significant levels.
These purified antigens also showed more sensitivity and
specificity in comparing patients with ABPA to simple Af
allergy.
From the results presented, it can be seen that Asp f 2 dem-
onstrated specific IgE in the sera of CF-ABPA patients, but
also showed reactivity with asthmatics and CF patients
without any allergy, i.e. high sensitivity, but low specifi-
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IgA, IgA1, IgA2, IgG1, IgG2, IgG3, and IgG4 antibodies against crude Aspergillus fumigatus antigens and various recombinant aller-gensFigure 2
IgA, IgA1, IgA2, IgG1, IgG2, IgG3, and IgG4 antibodies against crude Aspergillus fumigatus antigens and various recombinant aller-
gens. A – A. fumigatus extract, B – Asp f 1, C – Asp f 2, D – Asp f 3, E – Asp f 4, and F – Asp f 16.
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city. On the other hand, Asp f 3 showed high specificity,
but with low sensitivity. Although previous studies have
shown that Asp f 3 was significant in differentiating the CF
patient groups due to the presence of high levels of
Aspergillus specific IgE in their sera, we did not find this
clear cut difference in the present study [9,16].
In evaluating the ELISA and ImmunoCAP methods, our
results indicate that the former was more specific, but less
sensitive. The ImmunoCAP of recombinant allergens
reacted with more patients and demonstrated Af specific
IgE in the sera of ABPA with CF. Similarly a number of
asthmatics and CF without allergy also showed high levels
of specific IgE to the various antigens included in the
ImmunoCaps. ImmunoCAP of crude Aspergillus extract
demonstrated IgE in over 95% of ABPA-CF, but also
reacted with over 78% of asthmatics and 40% of CF
patients. Thus, the comparative specificity of ImmunoCap
using either crude or purified recombinant allergens of
Aspergillus is inferior to ELISA, but the latter is also not suf-
ficiently predictive to be acceptable as a reliable diagnostic
assay.
The usefulness of specific IgG subclasses in the diagnosis
of CF-ABPA has been previously suggested [14]. Although,
similar elevations in the levels of IgG1 and G4 were noted
in both CF groups in the present study, these differences
were not statistically significant. The discriminant func-
tion analysis using all features simultaneously classified
most patients in their respective groups. Although all the
17 ABPA-CF patients showed difference in their antibody
response, the results on comparison with other groups of
patients was found to be significant (Table 1). Generally a
discriminant capability of at least 90% is indicated for
adapting a test for differential diagnosis (Figure 3).
Conclusion
The results presented here indicate that the demonstration
of specific IgE, IgG, and IgA isotypes with recombinant Af
allergens has less usefulness in the diagnosis of CF-ABPA
than in non-CF-ABPA. However, in a previous study, Asp
f 3 demonstrated slightly enhanced levels of antibody in
the sera of patients with ABPA and CF compared to other
recombinant allergens [9]. Our results suggest that the
evaluation of different antibody isotypes in the sera using
a combination of recombinant Af allergens may have
added value in the diagnosis of CF with ABPA. The results
also suggest that additional relevant antigens and infor-
mation from cell-mediated immune responses are impor-
tant in the development of a more definitive diagnosis of
ABPA and for the discrimination of ABPA with CF from
other CF patients.
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